中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
22期
33-34
,共2页
地西他滨%恶性血液肿瘤%吉西他滨
地西他濱%噁性血液腫瘤%吉西他濱
지서타빈%악성혈액종류%길서타빈
Decitabine%Hematological malignancies%Gemcitabine
目的 分析地西他滨用于治疗恶性血液肿瘤的临床价值.方法 110例恶性血液肿瘤患者作为研究对象, 随机分为观察组和对照组, 每组55例.其中观察组患者采用地西他滨治疗, 对照组患者采用吉西他滨治疗, 观察两组的临床疗效和不良反应.结果 观察组治疗总有效率45.5%明显优于对照组21.8%;观察组不良反应发生率45.5%明显低于对照组70.9%, 差异具有统计学意义(P<0.05).结论 地西他滨治疗恶性血液肿瘤疾病具有显著疗效, 不良反应发生率低, 具有积极的临床推广价值.
目的 分析地西他濱用于治療噁性血液腫瘤的臨床價值.方法 110例噁性血液腫瘤患者作為研究對象, 隨機分為觀察組和對照組, 每組55例.其中觀察組患者採用地西他濱治療, 對照組患者採用吉西他濱治療, 觀察兩組的臨床療效和不良反應.結果 觀察組治療總有效率45.5%明顯優于對照組21.8%;觀察組不良反應髮生率45.5%明顯低于對照組70.9%, 差異具有統計學意義(P<0.05).結論 地西他濱治療噁性血液腫瘤疾病具有顯著療效, 不良反應髮生率低, 具有積極的臨床推廣價值.
목적 분석지서타빈용우치료악성혈액종류적림상개치.방법 110례악성혈액종류환자작위연구대상, 수궤분위관찰조화대조조, 매조55례.기중관찰조환자채용지서타빈치료, 대조조환자채용길서타빈치료, 관찰량조적림상료효화불량반응.결과 관찰조치료총유효솔45.5%명현우우대조조21.8%;관찰조불량반응발생솔45.5%명현저우대조조70.9%, 차이구유통계학의의(P<0.05).결론 지서타빈치료악성혈액종류질병구유현저료효, 불량반응발생솔저, 구유적겁적림상추엄개치.
Objective To analyze clinical value of decitabine in the treatment of hematological malignancies.Methods A total of 110 hematological malignancies patients as study subjects were randomly divided into observation group and control group, with 55 cases in each group. The observation group received decitabine for treatment, and the control group received gemcitabine. Clinical effects and adverse reactions of the two groups were observed.Results The observation group had much better total effective rate as 45.5% than 21.8% of the control group, and its incidence of adverse reactions was obviously lower as 45.5% than 70.9% of the control group. Their differences had statistical significance (P<0.05).Conclusion Decitabine provides precise effect in treating hematological malignancies, along with low incidence of adverse reactions. It contains positive value for clinical promotion.
